EU Regulator Backs NewAmsterdam's Cholesterol Drug Obicetrapib, Opening Path to Market

CHMP Gives Green Light to Obicetrapib for LDL-C Lowering

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for obicetrapib, a new oral, once-daily CETP inhibitor developed by NewAmsterdam Pharma. The recommendation covers both the 10 mg monotherapy (branded Ubeslo) and a fixed-dose combination of 10 mg obicetrapib with 10 mg ezetimibe (Evlarco), targeting adults with primary hypercholesterolemia—including heterozygous familial hypercholesterolemia and mixed dyslipidemia—who cannot reach their LDL-C goals with existing therapies.

The favorable opinion is based on three Phase III trials: BROADWAY, BROOKLYN, and TANDEM. In those studies, obicetrapib monotherapy reduced LDL-C by up to 40% versus placebo, while the combination with ezetimibe delivered reductions of around 50%. Both regimens showed a tolerability profile comparable to placebo. Michael Davidson, CEO of NewAmsterdam, called the milestone "an important step for an innovative treatment addressing residual cardiovascular risk in patients not adequately served by current statin-based regimens."

Under a licensing deal, privately owned Italian pharmaceutical group Menarini holds exclusive commercial rights to obicetrapib in Europe. NewAmsterdam stands to receive tiered royalties on net sales—starting in the low double digits and scaling to approximately 25%—along with additional milestone payments of up to €833 million upon achievement of clinical, regulatory, and sales targets. The next step is a final decision by the European Commission, expected later this year. Once granted, a centralized marketing authorization would apply across all EU member states plus Iceland, Liechtenstein, and Norway, clearing the way for Menarini’s commercial launch.

Why This Regulatory Win Matters for NewAmsterdam, Menarini, and the Cholesterol Market

Deal Economics and Payout Structure

The licensing agreement positions NewAmsterdam as a royalty-and-milestone player in Europe, not a direct seller. The tiered royalty structure (low-double-digit up to ~25%) is particularly advantageous because it gives the company significant upside if obicetrapib achieves strong commercial traction, while transferring the costs and risks of European marketing and distribution to Menarini. The €833 million in potential milestone payments—triggered by regulatory progress and sales thresholds—provides a near-to-medium-term cash catalyst, with the first commercial milestone likely tied to the expected EU approval. For Menarini, the deal adds a differentiated cardiovascular asset to its cardiometabolic portfolio, giving the group a branded presence in a market traditionally dominated by generic statins.

Obicetrapib’s Clinical Edge in a Statin-Heavy Market

The drug’s clinical profile gives it a distinct place: an oral, daily pill that delivers substantial LDL-C reductions without the need for injections (unlike PCSK9 inhibitors) and with a tolerability profile comparable to placebo. This could appeal to patients who do not reach LDL-C targets on statins alone or who cannot tolerate higher statin doses. However, the Phase III trials supporting the CHMP opinion were based on a surrogate endpoint (LDL-C lowering). The definitive cardiovascular outcomes trial, PREVAIL, recruited over 9,500 patients and completed enrollment in April 2024, but results are still pending. Until that data reads out, obicetrapib will be used primarily as an add-on to statins to achieve LDL-C goals, not yet as a therapy proven to reduce heart attacks or strokes—a distinction that will shape initial uptake and pricing negotiations.

Regulatory Momentum and the Outcomes Overhang

A European Commission decision typically follows a CHMP positive opinion within about 67 days, though the exact timeline may vary. Approval appears highly probable given the favorable recommendation. Beyond Europe, NewAmsterdam is pursuing a global strategy; U.S. regulatory filings are not discussed here but will likely depend on the PREVAIL data. The drug’s ultimate commercial ceiling—and NewAmsterdam’s valuation—rests heavily on whether obicetrapib can demonstrate a statistically significant reduction in major adverse cardiovascular events. If PREVAIL succeeds, the product could become a blockbuster contender; if it fails or underperforms, obicetrapib might remain a niche LDL-lowering tool, placing greater pressure on pricing and market access.

What Investors and Industry Players Should Watch Now

• NewAmsterdam shareholders should watch for a formal European Commission decision, likely within 2–3 months of the CHMP opinion. Approval will trigger a regulatory milestone payment from Menarini and set the royalty clock ticking on EU sales, providing a near-term cash catalyst.
• The PREVAIL cardiovascular outcomes trial is the single most important event for obicetrapib’s long-term value. Enrollment completed in April 2024, but the company has not disclosed the expected readout date. Investors should track any guidance from NewAmsterdam or conference presentations for a data timeline. A positive result would likely drive a major re-rating of the stock and open the door to U.S. submission.
• Menarini’s launch execution will be critical. The company must now prepare pricing and reimbursement dossiers across multiple EU markets, build awareness among cardiologists and primary care physicians, and negotiate placement on formularies. First-half sales post-launch will be an early indicator of market acceptance.
• Competitors in the non-statin lipid-lowering space (PCSK9 inhibitors, bempedoic acid) should note the oral convenience and favorable tolerability of obicetrapib. While PCSK9 injectables remain standards for very high-risk patients, a well-tolerated oral option with 40–50% LDL-C reduction could reshape prescribing patterns, especially in markets where cost and convenience dominate treatment decisions.